No profile data available.
Trevi Therapeutics, Inc. (TRVI) is a healthcare company in the skin treatment pharmaceuticals industry, based in New Haven, United States, with about 34 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$42.76 million. Its market capitalization was $1.88 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
Trevi Therapeutics reported $0 in revenue for fiscal year 2025.
$1.88 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (skin treatment pharmaceuticals) include Oruka Therapeutics, Inc. (ORKA), Arcutis Biotherapeutics, Inc. (ARQT), Almirall, S.a. (ALMRY), Avalo Therapeutics, Inc. (AVTX).